ClinVar Miner

Submissions for variant NM_014363.6(SACS):c.3782A>G (p.Asp1261Gly)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Molecular Genetics, Royal Melbourne Hospital RCV003994708 SCV004812703 uncertain significance Charlevoix-Saguenay spastic ataxia 2022-08-04 criteria provided, single submitter clinical testing This sequence change in SACS is predicted to replace aspartic acid with glycine at codon 1261, p.(Asp1261Gly). The aspartic acid residue is moderately conserved (100 vertebrates, UCSC), and is not located in an annotated domain. There is a moderate physicochemical difference between aspartic acid and glycine. The highest population minor allele frequency in gnomAD v2.1 is 0.0009% (1/113,450 alleles) in the European (non-Finnish) population, which is consistent with recessive disease. To our knowledge, this variant has not been reported in the literature in any individuals with SACS-related disease. Multiple lines of computational evidence have conflicting predictions for the missense substitution (4/6 algorithms predict benign). Based on the classification scheme RMH Modified ACMG Guidelines v1.5.1, this variant is classified as a VARIANT OF UNCERTAIN SIGNIFICANCE. Following criteria are met: PM2_Supporting.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.